Form 4: Silence Therapeutics Director and 10% Owner Increases Stake with Significant Share Purchases

Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, has significantly increased his direct beneficial ownership through multiple purchases of American Depositary Shares (ADS) totaling 85,838 ADS.

Summary

• Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc (SLN), acquired a total of 85,838 American Depositary Shares (ADS) through three separate transactions.
• The purchases occurred on May 26, 2025, May 27, 2025, and May 28, 2025.
• On May 26, 2025, 26,669 ADS were purchased at a price of $4.91 per ADS.
• On May 27, 2025, 50,000 ADS were purchased at a price of $5.13 per ADS.
• On May 28, 2025, 9,169 ADS were purchased at a price of $5.11 per ADS.
• Each American Depositary Share (ADS) is immediately convertible into three ordinary shares for no consideration.
• The total 85,838 ADS acquired are equivalent to 257,514 ordinary shares.
• Following these transactions, Richard Ian Griffiths' direct beneficial ownership stands at 11,322,075 American Depositary Shares.
• The transactions were made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 8

Explanation: The sentiment is highly positive as a Director and 10% Owner significantly increased their stake, signaling strong insider confidence in the company's value and future prospects.

Positives

• A Director and 10% Owner, Richard Ian Griffiths, increased his stake in Silence Therapeutics, signaling strong confidence in the company's future prospects.
• The acquisition of 85,838 ADS (equivalent to 257,514 ordinary shares) represents a notable increase in insider ownership.
• The purchases were executed at varying price points, indicating a sustained buying interest from a key insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an insider transaction, which is a common occurrence across all industries. In the biotechnology and pharmaceutical sector, insider buying can be viewed as a positive signal, especially from a significant shareholder and director, indicating confidence in the company's drug pipeline, clinical trial progress, or commercialization potential, which are critical drivers in this industry.

Related Party Transactions

• The reported transactions involve the purchase of American Depositary Shares by Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The insider buying by a Director and 10% Owner can be interpreted as a strong vote of confidence, potentially leading to increased investor interest and positive sentiment towards the stock.
• Employees: While not directly impacted, a positive signal from insider buying might indirectly boost employee morale and confidence in the company's stability and future.

Key Dates

Keywords

Silence Therapeutics, SLN, Form 4, Insider Trading, Director, 10% Owner, Share Purchase, American Depositary Shares, ADS, Equity Acquisition, Beneficial Ownership